We are live on ! Find out more
BOCH

Blue Owl Capital Holdings Portfolio holdings

AUM $665M
1-Year Est. Return 95.48%
This Fund
S&P 500
This Quarter Est. Return
+23.23%
1 Year Est. Return
+95.48%
3 Year Est. Return
+144.67%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$665M
AUM Growth
+$292M
Cap. Flow
+$238M
Cap. Flow %
35.84%
Top 10 Hldgs %
78.54%
Holding
93
New
17
Increased
13
Reduced
16
Closed
17

Top Buys

Rank Stock Value
1
SPCX
SpaceX
SPCX
+$238M
2
COF icon
Capital One
COF
+$22.9M
3
FISN
Deep Fission Inc
FISN
+$15.3M
4
LRMR icon
Larimar Therapeutics
LRMR
+$8.11M
5
ARTV
Artiva Biotherapeutics
ARTV
+$7.96M

Top Sells

Rank Stock Value
1
ENGN icon
enGene Therapeutics
ENGN
+$30.1M
2
MPLT
MapLight Therapeutics
MPLT
+$7.94M
3
CGEM icon
Cullinan Oncology
CGEM
+$5.49M
4
CVEO icon
Civeo
CVEO
+$4.78M
5
CMPS
Compass Pathways
CMPS
+$4.61M

Sector Composition

Rank Sector Weight
1 Healthcare 43.85%
2 Industrials 38.18%
3 Financials 11.05%
4 Technology 3.53%
5 Consumer Discretionary 1.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPCX
1
SpaceX
SPCX
$1.94T
$239M 35.97%
+1,398,815
New +$238M
AKTS
2
Aktis Oncology
AKTS
$1.34B
$99M 14.89%
3,070,219
-91,129
-3% -$1.87M
CGEM icon
3
Cullinan Oncology
CGEM
$1.37B
$28M 4.22%
1,539,764
-370,000
-19% -$5.49M
LRMR icon
4
Larimar Therapeutics
LRMR
$402M
$27.9M 4.21%
9,163,157
+2,043,150
+29% +$8.11M
NCDL icon
5
Nuveen Churchill Direct Lending
NCDL
$603M
$26.6M 4.01%
2,143,626
– –
MPLT
6
MapLight Therapeutics
MPLT
$636M
$26.2M 3.94%
729,929
-276,000
-27% -$7.94M
COF icon
7
Capital One
COF
$129B
$24M 3.62%
+119,757
New +$22.9M
OBDC icon
8
Blue Owl Capital
OBDC
$5.49B
$22.2M 3.35%
2,045,070
– –
FISN
9
Deep Fission Inc
FISN
$419M
$14.7M 2.22%
+1,333,333
New +$15.3M
DELL icon
10
Dell
DELL
$340B
$14.2M 2.14%
32,961
+19,062
+137% +$5.51M
HLLY icon
11
Holley
HLLY
$353M
$11.2M 1.68%
4,376,888
+140,000
+3% +$397K
EYPT icon
12
EyePoint Inc
EYPT
$374M
$10.9M 1.64%
762,594
-150,000
-16% -$2.01M
SGMT icon
13
Sagimet Biosciences
SGMT
$675M
$9.74M 1.47%
1,260,544
+926,667
+278% +$6.3M
CRVS icon
14
Corvus Pharmaceuticals
CRVS
$1.12B
$9.09M 1.37%
608,600
+63,600
+12% +$883K
ARTV
15
Artiva Biotherapeutics
ARTV
$528M
$8.48M 1.28%
+874,542
New +$7.96M
CMPX icon
16
Compass Therapeutics
CMPX
$393M
$7.94M 1.19%
3,624,076
+682,551
+23% +$2.02M
CNDT icon
17
Conduent
CNDT
$247M
$7.35M 1.11%
5,036,595
– –
RYTM icon
18
Rhythm Pharmaceuticals
RYTM
$6.96B
$6.82M 1.03%
61,455
– –
CMPS
19
Compass Pathways
CMPS
$2.1B
$6.37M 0.96%
450,000
-454,504
-50% -$4.61M
RARE icon
20
Ultragenyx Pharmaceutical
RARE
$1.41B
$6.1M 0.92%
182,638
-120,000
-40% -$2.98M
PVLA
21
Palvella Therapeutics
PVLA
$2.18B
$5.54M 0.83%
36,259
+5,000
+16% +$607K
IMA
22
ImageneBio Inc
IMA
$56.9M
$5.41M 0.81%
917,692
-41,645
-4% -$235K
CMPS
23
CALL
Compass Pathways
CMPS
$2.1B
$5.18M 0.78%
1,670,500
+770,500
+86% +$7.82M
VRDN icon
24
Viridian Therapeutics
VRDN
$2.58B
$4.78M 0.72%
+260,000
New +$4.19M
IMMX icon
25
Immix Biopharma
IMMX
$881M
$4.51M 0.68%
437,552
-110,000
-20% -$1.02M
1
2 3 4

Similar funds

SLWA
San Luis Wealth Advisors San Luis Obispo, California $664M AUM 19.82% 1-Year Est. Return
CBB
Citizens Business Bank Ontario, California $664M AUM 33.78% 1-Year Est. Return
ARG
Advisory Resource Group Tulsa, Oklahoma $665M AUM 29.27% 1-Year Est. Return
MC
McMorgan & Co San Francisco, California $664M AUM 11.57% 1-Year Est. Return
CCM
Cantillon Capital Management New York $665M AUM 25.91% 1-Year Est. Return
AG
Advocate Group Minnetonka, Minnesota $665M AUM 22.13% 1-Year Est. Return
CGIM
Capital Group Investment Management Raffles Quay, Singapore $664M AUM 34.11% 1-Year Est. Return
CG
Cynosure Group Salt Lake City, Utah $666M AUM 18.54% 1-Year Est. Return

Blue Owl Capital Holdings's Q2 2026 Portfolio in Review

As of Q2 2026, Blue Owl Capital Holdings held 93 positions worth $665M, up 79% from $372M the previous quarter. Its ten largest holdings account for 79% of the portfolio.

Blue Owl Capital Holdings deployed $238M of net new capital in Q2 2026, opening 17 new positions and adding to 13 existing holdings. Its largest new stake was SpaceX: 1,398,815 shares worth $239M.

By sector, the portfolio is most concentrated in Healthcare at 44% of assets, down from 76% a quarter earlier, followed by Industrials and Financials.

On the sell side, the largest reduction was MapLight Therapeutics, an estimated $7.94M trimmed.

  • Blue Owl Capital Holdings's largest Q2 2026 buy was SpaceX: 1,398,815 shares worth $239M.
  • Blue Owl Capital Holdings added most to Larimar Therapeutics in Q2 2026, an estimated $8.11M increase.
  • Blue Owl Capital Holdings's biggest Q2 2026 reduction was MapLight Therapeutics, cutting an estimated $7.94M.
  • Blue Owl Capital Holdings fully exited enGene Therapeutics in Q2 2026, selling an estimated $30.1M.
  • Blue Owl Capital Holdings's ten largest holdings make up 79% of its $665M portfolio in Q2 2026.
  • Blue Owl Capital Holdings opened 17 new positions and closed 17 in Q2 2026.
  • Blue Owl Capital Holdings's portfolio value rose 79% quarter-over-quarter to $665M.

Based on Blue Owl Capital Holdings's 13F filing for Q2 2026, filed 11 Aug 2026.